Johnson & Johnson’s RYBREVANT and LAZCLUZE show unprecedented survival advantage in lung cancer trial
Johnson & Johnson has revealed transformative results from the Phase 3 MARIPOSA clinical trial, positioning the combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) as a ... Read More